Floatz Rating
B60/100
Confidence
Indicative
Sponsor
UNC Lineberger Comprehensive Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03602157CT.gov Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | — | Active Not Recruiting | — | — | — |
NCT01118013CT.gov Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lymphoproliferative Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ondansetron (this asset) | UNC Lineberger Comprehensive Cancer Center | P2 | B · 60 |
| Darbepoetin Alfa | Mayo Clinic | P3 | BB |
| Epoetin Alfa | Mayo Clinic | P3 | BB |
| Fludarabine | Beijing Immunochina Medical Science & Technology Co., Ltd. | P2 | BB |
| Amitriptyline | Alliance for Clinical Trials in Oncology | P3 | BB |
| Sodium Ferric Gluconate | Mayo Clinic | P3 | BB |
| Tabelecleucel | Pierre Fabre Medicament | P3 | BB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Alliance for Clinical Trials in Oncology | P3 | BB |
| Baclofen | Alliance for Clinical Trials in Oncology | P3 | BB |
+40 more in the Lymphoproliferative Syndrome cohort
Other indications for Ondansetron
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cancer Of Unknown Primary Site | — | P3 | BB · 71 |
| Childhood Neoplasm | — | P3 | BB · 66 |
| Alcohol Abuse | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ondansetron in Lymphoproliferative Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ondansetron-lymphoproliferative-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →